본문으로 건너뛰기
← 뒤로

Finding the most promising indications for novel treatments in oncology.

NPJ precision oncology 2026 Vol.10(1)

Eckhoff M, Klingelschmitt S, Van Ruijssevelt L, Grossmann S, Zichner T, Stümpges P, Roschewitz D, Mlecnik B, Merger M, Graen P, Kumar J, Devereson A, Wurzer S, Bleys J, Albrecht B, Hach D, Haslinger C

📝 환자 설명용 한 줄

Tackling cancer with effective therapies is a major challenge our society faces with significant costs and complexities of designing and validating treatments.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Eckhoff M, Klingelschmitt S, et al. (2026). Finding the most promising indications for novel treatments in oncology.. NPJ precision oncology, 10(1). https://doi.org/10.1038/s41698-026-01352-x
MLA Eckhoff M, et al.. "Finding the most promising indications for novel treatments in oncology.." NPJ precision oncology, vol. 10, no. 1, 2026.
PMID 41882305

Abstract

Tackling cancer with effective therapies is a major challenge our society faces with significant costs and complexities of designing and validating treatments. In this article we show that representation learning based on real-world data can suggest indications for which a chosen mechanism of action is likely to be effective. We trained a machine learning model to rank histology-based malignant indications against expected biological relevance of anti-PD-1 treatment, leveraging reference indications and an embedding generating approach for features based on events in the patient's medical journey. We call our approach INSPIRE. When restricting the model to data before broad establishment of PD-1 inhibitors in the clinic, the method successfully prioritizes 70% of subsequent approvals. This indicates that INSPIRE could accelerate the process of selecting, testing and eventually treating patients with effective drugs, therefore reducing costs and improving care for patients.